Expert Speaker Faculty

Take a look at the esteemed speaker faculty for the 7th RAS-Targeted Drug Development Summit.

Haibing Deng, Executive Director, Medicinal Chemistry Abbisko Therapeutics

Haibing Deng

Executive Director, Medicinal Chemistry
Abbisko Therapeutics
Lauren Stopfer, Executive Director, Proteomics & Innovation, Aethon Therapeutics

Lauren Stopfer

Executive Director, Proteomics & Innovation
Aethon Therapeutics
Soumit Basu, Senior Medical Director, Affini-T Therapeutics

Soumit Basu

Senior Medical Director
Affini-T Therapeutics
Emily Chan, Executive Medical Director, Global Development Lead, Amgen Inc.

Emily Chan

Executive Medical Director, Global Development Lead
Amgen Inc.
Yuliya Katlinskaya, Sr Principal Scientist, Amgen Inc.

Yuliya Katlinskaya

Sr Principal Scientist
Amgen Inc.
Reagan Jarvis, Chief Executive Officer & Co-Founder, Anocca

Reagan Jarvis

Chief Executive Officer & Co-Founder
Anocca
Katie Smith, Director - Oncology, Arvinas, Inc.

Katie Smith

Director - Oncology
Arvinas, Inc.
Michael Niedbala, Executive Director, Early Oncology Projects, AstraZeneca

Michael Niedbala

Executive Director, Early Oncology Projects
AstraZeneca
Andrew Norris, Senior Director, Research, BCN Biosciences

Andrew Norris

Senior Director, Research
BCN Biosciences
Michael Sweeney, Director - Business Development & Operations, Biodesix

Michael Sweeney

Director - Business Development & Operations
Biodesix
Kerstin Sinkevicius, Vice President, Pharmacology, BridgeBio Oncology Therapeutics

Kerstin Sinkevicius

Vice President, Pharmacology
BridgeBio Oncology Therapeutics
Hua Gong, VP, Translational Medicine, BridgeBio Oncology Therapeutics

Hua Gong

VP, Translational Medicine
BridgeBio Oncology Therapeutics
Thomas Spires, Senior Director, Translational Medicine, Bristol Myers Squibb

Thomas Spires

Senior Director, Translational Medicine
Bristol Myers Squibb
Cheng Chen, Senior Medical Director, Clinical Lead for KRAS G12C Program, D3 Bio

Cheng Chen

Senior Medical Director, Clinical Lead for KRAS G12C Program
D3 Bio
Jing Zhang, Vice President, Head, Discovery, D3 Blo

Jing Zhang

Vice President, Head, Discovery
D3 Blo
Jia Luo, Thoracic Medical Oncologist and Instructor in Medicine Dana-Farber Cancer Institute, Harvard Medical School

Jia Luo

Thoracic Medical Oncologist and Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Pete DeMuth, Chief Scientific Officer, Elicio Therapeutics

Pete DeMuth

Chief Scientific Officer
Elicio Therapeutics
Rebecca Heist, Professor of Medicine Harvard Medical School & Massachusetts General Hospital

Rebecca Heist

Professor of Medicine
Harvard Medical School & Massachusetts General Hospital
Anita Bellail, Discovery and Development of a Molecular Glue Co-Degrader Targeting KRAS Mutant and CRAF via a Novel E3 Ligase. HB Therapeutics, Inc.

Anita Bellail

Discovery and Development of a Molecular Glue Co-Degrader Targeting KRAS Mutant and CRAF via a Novel E3 Ligase.
HB Therapeutics, Inc.
Andrea Wang Gillam, Chief Medical Officer & Global Head of Research & Development, Jacobio Pharmaceuticals Inc

Andrea wang gillam

Chief Medical Officer & Global Head of Research & Development
Jacobio Pharmaceuticals Inc
Nicholas Larsen, Senior Director - Biophysics & Structural Biology, Kestrel Therapeutics Inc

Nicholas Larsen

Senior Director - Biophysics & Structural Biology
Kestrel Therapeutics Inc
Ali Smith, Senior Scientist, Kura Oncology

Ali Smith

Senior Scientist
Kura Oncology
Aaron Hata, Associate Professor, Massachusetts General Hospital

Aaron Hata

Associate Professor
Massachusetts General Hospital
Eric Haura, Associate Center Director, Clinical Science, Moffitt Cancer Center

Eric Haura

Associate Center Director, Clinical Science
Moffitt Cancer Center
Meagan Ryan, Senior Scientist Biology & Translational Sciences, Nested Therapeutics

Meagan Ryan

Senior Scientist Biology & Translational Sciences
Nested Therapeutics
Philip Komarnitsky, Chief Medical Officer, Nested Therapeutics

Philip Komarnitsky

Chief Medical Officer
Nested Therapeutics
Soo-Youl Kim, Chief Executive Officer & Principal Scientist, New Cancer Cure-Bio & National Cancer Center

Soo-Youl Kim

Chief Executive Officer & Principal Scientist
New Cancer Cure-Bio & National Cancer Center
Shohei Koide, Professor - Biologics Design, New York University Grossman School of Medicine

Shohei Koide

Professor - Biologics Design
New York University Grossman School of Medicine
Huaixiang Hao, Co-Founder, Vice President & Head of Research, PAQ Therapeutics

Huaixiang Hao

Co-Founder, Vice President & Head of Research
PAQ Therapeutics
Greg Jones, Senior Principal Scientist, Pfizer

Greg Jones

Senior Principal Scientist
Pfizer
Brent Meadows, CBO, Polymed Biopharmaceuticals

Brent Meadows

CBO
Polymed Biopharmaceuticals
Said Sebti, Professor, Virginia Commonwealth University, Founder, Prescient Therapeutics

Said Sebti

Professor, Virginia Commonwealth University, Founder
Prescient Therapeutics
Dhirendra Simanshu, Group Lead RAS Initiative, Frederick National Laboratory

Dhirendra Simanshu

Group Lead
RAS Initiative, Frederick National Laboratory
Jingjing Jiang, Vice President, Cancer Pharmacology, Translational Research, Revolution Medicines

Jingjing Jiang

Vice President, Cancer Pharmacology, Translational Research
Revolution Medicines
Ashley Williams, Director - Research & Development, SiVEC Biotechnologies

Ashley Williams

Director - Research & Development
SiVEC Biotechnologies
Charly Chahwan, Co-Founder & Chief Scientific Officer, SyntheX

Charly Chahwan

Co-Founder & Chief Scientific Officer
SyntheX
Peter Winter, Principal Investigator & Co-Director, Project Ex Vivo The Broad Institute of MIT & Harvard

Peter Winter

Principal Investigator & Co-Director, Project Ex Vivo
The Broad Institute of MIT & Harvard
Andrew Waters, Assistant Professor University of Cincinnati Cancer Center

Andrew Waters

Assistant Professor
University of Cincinnati Cancer Center
Kristen Bryant, Assistant Professor, Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Kristen Bryant

Assistant Professor, Department of Pharmacology, Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill
Zhiyong Wang, CSO, Venquis Therapeutics

Zhiyong Wang

CSO
Venquis Therapeutics
Silvia Coma, Senior Director, Translational & Preclinical Research, Verastem Oncology

Silvia Coma

Senior Director, Translational & Preclinical Research
Verastem Oncology
Jonathan Pachter, Chief Scientific Officer, Verastem. inc

Jonathan Pachter

Chief Scientific Officer
Verastem. inc
Hui Miao, Senior Scientist, Vividion Therapeutics

Hui Miao

Senior Scientist
Vividion Therapeutics
conference
Explore the Agenda

Hear the latest industry breakthroughs, cutting edge strategies as well as overcome RAS drug bottlenecks during our packed agenda consisting of deep dive workshops, interactive roundtables and data-driven case studies.

View Presentations & Speakers
summit
Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of RAS biopharma deals.

Explore Sponsorship Options
conference
Join RAS Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.

Register Now